Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model
This study of early CIN biopsies (25 CIN1 and 65 CIN2) with long follow-up was done to validate, in a new group of patients, the value of Ki67 immuno-quantitative features to predict high CIN grade in a follow-up biopsy (often denoted to as “progression”), as described in a previous study. Each biop...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2004-01-01
|
| Series: | Cellular Oncology |
| Online Access: | http://dx.doi.org/10.1155/2004/108305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561884607283200 |
|---|---|
| author | Arnold-Jan Kruse Jan P. A. Baak Emiel A. Janssen Kjell-Henning Kjellevold Bent Fianec Kjell Lovslett Johan Bergh Stanley Robboy |
| author_facet | Arnold-Jan Kruse Jan P. A. Baak Emiel A. Janssen Kjell-Henning Kjellevold Bent Fianec Kjell Lovslett Johan Bergh Stanley Robboy |
| author_sort | Arnold-Jan Kruse |
| collection | DOAJ |
| description | This study of early CIN biopsies (25 CIN1 and 65 CIN2) with long follow-up was done to validate, in a new group
of patients, the value of Ki67 immuno-quantitative features to predict high CIN grade in a follow-up biopsy (often denoted to as
“progression”), as described in a previous study. Each biopsy in the present study was classified with the previously described
Ki67-model (consisting of the stratification index and the % positive nuclei in the middle third layer of the epithelium) as
“low-risk” or “high-risk”, and matched with the follow-up outcome (progression-or-not). Furthermore, it was studied whether
subjective evaluation of the Ki67 sections by experienced pathologists, who were aware of the prognostic quantitative Ki67
features, could also predict the outcome. Thirdly, the reproducibility of routine use of the quantitative Ki67-model was assessed.
Fifteen cases progressed (17%) to CIN3, 2/25 CIN1 (8%) and 13/65 CIN2 (20%), indicating that CIN grade (as CIN1 or CIN2) is
prognostic and that the percentage of CIN1 and CIN2 cases with progression in the present study is comparable to many previous
studies. However, the quantitative Ki67 model had stronger prognostic value than CIN grade as none of the 40 “Ki67-model
low-risk” patients progressed, in contrast to 15 (30%) of the 50 “Ki67-model high-risk” patients (p < 0.001). In multivariate
analysis, neither CIN grade nor any of the other quantitative Ki67 features added to the abovementioned prognostic Ki67-model.
Subjective analysis of the Ki67 features was also prognostic, although quantitative assessments gave better results. Routine
application of the quantitative Ki67-model in CIN1 and CIN2 was well reproducible. In conclusion, the results confirm that
quantitative Ki67 features have strong prognostic value for progression in early CIN lesions. |
| format | Article |
| id | doaj-art-017344896443454091cc063c86442e62 |
| institution | Kabale University |
| issn | 1570-5870 1875-8606 |
| language | English |
| publishDate | 2004-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cellular Oncology |
| spelling | doaj-art-017344896443454091cc063c86442e622025-02-03T01:23:57ZengWileyCellular Oncology1570-58701875-86062004-01-01261-2132010.1155/2004/108305Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk ModelArnold-Jan Kruse0Jan P. A. Baak1Emiel A. Janssen2Kjell-Henning Kjellevold3Bent Fianec4Kjell Lovslett5Johan Bergh6Stanley Robboy7Department of Pathology, Rogaland Central Hospital (=SiR), Stavanger, Norway and Free University, NorwayDepartment of Pathology, Rogaland Central Hospital (=SiR), Stavanger, Norway and Free University, NorwayDepartment of Pathology, Rogaland Central Hospital (=SiR), Stavanger, Norway and Free University, NorwayDepartment of Pathology, Rogaland Central Hospital (=SiR), Stavanger, Norway and Free University, NorwayDepartment of Gynecology, Rogaland Central Hospital (=SiR), Stavanger, Norway and Free University, NorwayDepartment of Gynecology, Rogaland Central Hospital (=SiR), Stavanger, Norway and Free University, NorwayMadla Gynecology, Amsterdam, The NetherlandsDepartment of Pathology, Duke University Medical Center, Durham, North Carolina, USAThis study of early CIN biopsies (25 CIN1 and 65 CIN2) with long follow-up was done to validate, in a new group of patients, the value of Ki67 immuno-quantitative features to predict high CIN grade in a follow-up biopsy (often denoted to as “progression”), as described in a previous study. Each biopsy in the present study was classified with the previously described Ki67-model (consisting of the stratification index and the % positive nuclei in the middle third layer of the epithelium) as “low-risk” or “high-risk”, and matched with the follow-up outcome (progression-or-not). Furthermore, it was studied whether subjective evaluation of the Ki67 sections by experienced pathologists, who were aware of the prognostic quantitative Ki67 features, could also predict the outcome. Thirdly, the reproducibility of routine use of the quantitative Ki67-model was assessed. Fifteen cases progressed (17%) to CIN3, 2/25 CIN1 (8%) and 13/65 CIN2 (20%), indicating that CIN grade (as CIN1 or CIN2) is prognostic and that the percentage of CIN1 and CIN2 cases with progression in the present study is comparable to many previous studies. However, the quantitative Ki67 model had stronger prognostic value than CIN grade as none of the 40 “Ki67-model low-risk” patients progressed, in contrast to 15 (30%) of the 50 “Ki67-model high-risk” patients (p < 0.001). In multivariate analysis, neither CIN grade nor any of the other quantitative Ki67 features added to the abovementioned prognostic Ki67-model. Subjective analysis of the Ki67 features was also prognostic, although quantitative assessments gave better results. Routine application of the quantitative Ki67-model in CIN1 and CIN2 was well reproducible. In conclusion, the results confirm that quantitative Ki67 features have strong prognostic value for progression in early CIN lesions.http://dx.doi.org/10.1155/2004/108305 |
| spellingShingle | Arnold-Jan Kruse Jan P. A. Baak Emiel A. Janssen Kjell-Henning Kjellevold Bent Fianec Kjell Lovslett Johan Bergh Stanley Robboy Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model Cellular Oncology |
| title | Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model |
| title_full | Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model |
| title_fullStr | Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model |
| title_full_unstemmed | Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model |
| title_short | Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model |
| title_sort | ki67 predicts progression in early cin validation of a multivariate progression risk model |
| url | http://dx.doi.org/10.1155/2004/108305 |
| work_keys_str_mv | AT arnoldjankruse ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT janpabaak ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT emielajanssen ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT kjellhenningkjellevold ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT bentfianec ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT kjelllovslett ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT johanbergh ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel AT stanleyrobboy ki67predictsprogressioninearlycinvalidationofamultivariateprogressionriskmodel |